Rani Therapeutics Holdings

Needle-Free Oral Biologics Will Serve Aging Global Demand

AnalystHighTarget

Not Invested

Consensus Narrative from 4 Analysts

Published

14 Aug 25

Updated

21 Aug 25

AnalystHighTarget's Fair Value

US$9.00

93.3% undervalued

21 Aug

US$0.60

-80.2%

8.6%

-80.2%

8.6%

Author's Valuation

US$9.0

93.3% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$9.0

93.3% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

66.21%

Pharma revenue growth rate

0.58%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$18.77m

Earnings '28

61.42x

PE Ratio '28

US$1.15b

Market Cap '28

US$1.15b

Market Cap '28

105.23m

No. shares '28

US$10.96

Share Price '28

US$10.96 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$9.00

Fair Value '25